Can GLP-1s Double Colorectal Cancer Risk?
-
By
September 5, 2025
-
2 min
-
1
Meta-analysis of 5 million patients assessing GLP-1 RAs and CRC risk.
-
2
More than doubled CRC risk with GLP-1 RAs (RR 2.31).
-
3
Quality of studies rated low to moderate risk of bias.
-
4
No significant difference in CRC risk when compared to DPP-4 inhibitors or metformin.
-
5
Need for further investigation on long-term safety of GLP-1 RAs.
-
6
Recommendations for personalized risk assessment in patients with preexisting CRC risk factors.
-
7
Source: BMC Gastroenterology.
-
A meta-analysis evaluated the association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and colorectal cancer (CRC) risk in over 5 million patients with type 2 diabetes. The study found that GLP-1 RA users had more than double the risk of developing CRC (RR 2.31; p < 0.0001), though differences in CRC incidence compared to other medications like DPP-4 inhibitors and metformin were not significant (OR: 1.73; p = 0.61). Authors advocate for further long-term studies and careful patient assessment regarding CRC risk when prescribing GLP-1 RAs.
-
1
Meta-analysis of 5 million patients assessing GLP-1 RAs and CRC risk.
-
2
More than doubled CRC risk with GLP-1 RAs (RR 2.31).
-
3
Quality of studies rated low to moderate risk of bias.
-
4
No significant difference in CRC risk when compared to DPP-4 inhibitors or metformin.
-
5
Need for further investigation on long-term safety of GLP-1 RAs.
-
6
Recommendations for personalized risk assessment in patients with preexisting CRC risk factors.
-
7
Source: BMC Gastroenterology.
Listen Tab content
